紫杉醇联合蒽环类药物治疗晚期乳腺癌的临床观察

Combination of paclitaxel and anthracycline for treatment of patients with advanced breast cancer

目的观察紫杉醇联合吡柔比星（THP）／表阿霉素（E-ADM）治疗晚期乳腺癌患者的临床疗效和不良反应。方法95例患者均为晚期乳腺癌，化疗方案为THP50mg／m^2或E—ADM70mg／m^2，快速静滴15min，d1；国产紫杉醇135～175mg／m^2，静滴3h，d2。21d为一个周期，连用2个周期以上评价疗效。结果全组95例均可评价疗效，总有效率为40.0％。完全缓解率为15．8％，部分缓解率为24．2％。无治疗相关死亡，丰要不良反成为骨髓抑制和脱发。THP组脱发发生率较E-ADM组少，差异有显著性。结论紫杉醇联合THP/E-ADM化疗晚期乳腺癌缓解率较高，不良夏应可耐受，是治疗晚期乳腺癌安全有效的化疗方案。

Objective To investigate efficacy of combination of paclitaxel and anthraeycline in treatment of advanced breast cancer, and its toxicity. Methods Ninety-five patients with advanced breast cancer received this regimen （50 mg/m^2 of THP or 70 mg/m^2 of E-ADM intravenous infusion for 15 min, day 1 ; 135-175 mg/m^2 of paclitaxel, intravenous infusion for 3 hr, day 2） , every 21 days was a cycle. Efficacy and toxicity were evaluated after 2 eycles. Results Total response rate was 40. 0% , with 15 eases of complete remission（ CR 15.8% ） and 23 cases of partial remission（ PR 24.2% ）. No treatment-related death occurred. Myelosuppression and alopecia were main toxicity. Group of THP was better than group of E-ADM in alopecia, with significant difference. Conclusion The combination of paclitaxel and THP/E-ADM may achieve a high response rate with toxicity tolerable by patients with advanced hreast cancer.